Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWD
2024-511711-21-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety (surgical morbidity and mortality and treatment-related adverse events within 90 days of surgery) and Feasibility of durvalumab consolidation after surgery. Planned start Jun 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511711-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511711-21-00.